NCT07172412View on ClinicalTrials.gov

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Extensive Stage Lung Small Cell Cancer
Interventions
DRUG

Selinexor

Selinexor 60 mg biw q21d

DRUG

Anlotinib

Anlotinib 12mg d1-14 qd PO

BIOLOGICAL

DLL3 CAR-NK cells

1.0×10\^9 DLL3-CAR-NK+ cells d5 q6w

DRUG

Etoposide + Cisplatin/Carboplatin

Etoposide 100mg/m\^2 d1-3+ cisplatin 75mg/m\^2 d1-3 or Carboplatin AUC5

DRUG

Tislelizumab/Atezolizumab/ Durvalumab/Benmelstobart/Toripalimab/Serplulimab

Use immunotherapy according to the standard immunotherapy-combined-chemotherapy protocol.

Trial Locations (1)

Unknown

Tianjin Medical University Cancer Institute and Hospital, Tianjin, China 300060, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT07172412 - Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter